📘

Definitions

1

Non-dysgerminomatous ovarian malignant germ cell tumor definition

Ovarian malignant germ cell tumors arise from ovarian germ cells; the non-dysgerminomatous subset excludes pure dysgerminoma and captures malignant primitive or teratomatous histologies such as yolk sac tumor, embryonal carcinoma, choriocarcinoma, immature teratoma, and mixed malignant germ cell tumor.

CASE_DEFINITION Rare gynecologic oncology disease grouping

Show evidence (1 reference)

PMID:37372675 SUPPORT Human Clinical

"Precursory germ cells of the ovary form the basis of GCT. They are histologically classified into primitive GCT, teratomas, and monodermal and somatic-type tumours associated with dermoid cysts."

This review supports the ovarian germ-cell origin and major histologic classification framework used for this non-dysgerminomatous disease entry.

◆

Subtypes

5

Ovarian yolk sac tumor

Endodermal sinus/yolk sac tumor is an aggressive non-dysgerminomatous histology that commonly produces alpha-fetoprotein and has clinically important marker kinetics during chemotherapy.

Show evidence (1 reference)

PMID:27401840 SUPPORT Human Clinical

"The ovarian yolk sac tumor (OYST) is a very rare malignancy arising in young women."

This supports ovarian yolk sac tumor as a rare malignant ovarian germ cell tumor subtype.

Ovarian immature teratoma

Malignant teratoma composed of immature tissues; fully resected stage I disease is a major management controversy because pediatric and adult practices differ on postoperative chemotherapy.

Show evidence (1 reference)

PMID:38544795 SUPPORT Human Clinical

"Ovarian immature teratoma (IT) is a rare neoplasm comprising ∼3% of ovarian cancers, occurring primarily in young females."

This supports immature teratoma as a rare ovarian neoplasm in the target population.

Ovarian embryonal carcinoma

Rare primitive non-dysgerminomatous ovarian germ cell tumor that may occur alone or as part of a mixed malignant germ cell tumor.

Show evidence (1 reference)

PMID:33142349 SUPPORT Human Clinical

"To describe the clinical and ultrasound characteristics of three types of rare malignant ovarian germ cell tumor: embryonal carcinoma, non-gestational choriocarcinoma and malignant mixed germ cell tumor."

This imaging series supports ovarian embryonal carcinoma as one of the rare malignant ovarian germ cell tumor types in this non-dysgerminomatous group.

Non-gestational ovarian choriocarcinoma

Rare trophoblastic non-dysgerminomatous ovarian germ cell tumor that is associated with high beta-human chorionic gonadotropin.

Show evidence (1 reference)

PMID:33142349 SUPPORT Human Clinical

"To describe the clinical and ultrasound characteristics of three types of rare malignant ovarian germ cell tumor: embryonal carcinoma, non-gestational choriocarcinoma and malignant mixed germ cell tumor."

This supports non-gestational ovarian choriocarcinoma as a rare malignant ovarian germ cell tumor type.

Mixed Malignant Germ Cell Tumor

Tumors containing more than one malignant ovarian germ cell component; mixed tumors may combine yolk sac tumor, immature teratoma, embryonal carcinoma, choriocarcinoma, or dysgerminoma components.

Show evidence (1 reference)

PMID:33142349 SUPPORT Human Clinical

"To describe the clinical and ultrasound characteristics of three types of rare malignant ovarian germ cell tumor: embryonal carcinoma, non-gestational choriocarcinoma and malignant mixed germ cell tumor."

This supports malignant mixed germ cell tumor as one of the rare malignant ovarian germ cell tumor types represented in this entry.

⚙

Pathophysiology

5

Primordial Germ Cell-Derived Malignancy

The disease arises from ovarian germ-cell lineage cells rather than ovarian surface epithelial cells. Malignant transformation creates primitive or teratomatous germ-cell histologies that remain biologically distinct from common epithelial ovarian carcinomas.

primordial germ cell link

germ cell development link ⚠ ABNORMAL

ovary link

Downstream

Non-Dysgerminomatous Differentiation Programs Transformed germ cells differentiate into embryonic or extraembryonic malignant histologies.

Show evidence (1 reference)

PMID:33435376 SUPPORT Human Clinical

"The malignant ovarian GCTs (mOGCTs) are assumed to derive from primordial germ cells (PGCs) with inherited or somatically acquired alterations [2]."

This source directly supports primordial germ cells as the inferred cell-of-origin for malignant ovarian germ cell tumors.

Non-Dysgerminomatous Differentiation Programs

Non-dysgerminomatous ovarian germ cell tumors show differentiation toward embryonic tissues, including embryonal carcinoma and immature teratoma, or extraembryonic tissues, including yolk sac tumor and non-gestational choriocarcinoma.

cell differentiation link ⚠ ABNORMAL

Downstream

Large Unilateral Marker-Secreting Ovarian Tumor Differentiated malignant components form bulky ovarian tumors and secrete component-specific markers.

Show evidence (1 reference)

PMID:33435376 SUPPORT Human Clinical

"The primitive GCTs are subdivided into the ovarian counterpart of the male testicular seminoma, dysgerminoma (DG), and non-DGs. The development of non-DGs is characterized by differentiation into cell histologies that mimic embryonic tissues (embryonal carcinoma (EC), teratoma) and..."

This supports the specific non-dysgerminomatous differentiation programs represented in this entry.

Yolk Sac Tumor Molecular Alteration

Ovarian yolk sac tumors have limited molecular data, but profiled tumors can harbor clinically relevant alterations in oncogenic signaling and chromatin regulatory genes, including KRAS and ARID1A in one series and PIK3CA in persistent or recurrent disease.

KRAS link PIK3CA link

cell population proliferation link ↑ INCREASED phosphatidylinositol 3-kinase/protein kinase B signal transduction link ⚠ ABNORMAL

Downstream

Platinum Sensitivity and Resistance Molecularly heterogeneous disease remains usually platinum-sensitive, but persistent or recurrent cases need better risk stratification.

Show evidence (2 references)

PMID:33435376 SUPPORT Human Clinical

"A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in KRAS, KIT, ARID1A."

This molecular profiling series supports recurrent actionable oncogenic alterations in a subset of ovarian yolk sac tumors; KIT is not modeled as a gene for this non-dysgerminomatous page because the same paper and the wider literature associate KIT most strongly with dysgerminoma biology.

PMID:38733954 SUPPORT Human Clinical

"For the 8 persistent and recurrent OYST: cancer driver genes including ANKRD36, ANKRD62, DNAH8, MUC5B, NUP205, RYR2, STARD9, MUC16, TTN, ARID1A and PIK3CA were frequently mutated; cell cycle, ABC transporters, HR, NHEJ and AMPK signal pathway demonstrated as the most significantly enriched..."

This larger yolk sac tumor series supports molecular alteration of persistent or recurrent disease and specifically includes PIK3CA.

Large Unilateral Marker-Secreting Ovarian Tumor

Non-dysgerminomatous ovarian germ cell tumors often form large unilateral ovarian masses. Tumor components can secrete alpha-fetoprotein or beta-human chorionic gonadotropin, supporting diagnosis and response monitoring.

cell population proliferation link ↑ INCREASED

ovary link

Downstream

Platinum Sensitivity and Resistance Diagnosis and monitoring by imaging and serum markers guide surgery, chemotherapy, and follow-up.

Show evidence (2 references)

PMID:33142349 SUPPORT Human Clinical

"Beta-human chorionic gonadotropin levels were highest in non-gestational choriocarcinomas and alpha-fetoprotein levels were highest in malignant mixed germ cell tumors."

This supports component-specific tumor marker secretion in rare ovarian non-dysgerminomatous germ cell tumor histologies.

PMID:33142349 SUPPORT Human Clinical

"A unilateral, large solid tumor with inhomogeneous echogenicity of the solid tissue and with dispersed small cystic areas in a young woman should raise the suspicion of a rare malignant germ cell tumor."

This supports the bulky unilateral ovarian mass presentation for the non-dysgerminomatous tumor types covered by this imaging series.

Platinum Sensitivity and Resistance

Most malignant ovarian germ cell tumors are chemosensitive, with cisplatin-based regimens producing high survival rates, but relapse, persistent disease, and long-term toxicities motivate dose optimization and alternatives.

apoptotic process link ↑ INCREASED

Show evidence (2 references)

PMID:37820296 SUPPORT Human Clinical

"Excellent outcomes, even in widely metastatic disease using cisplatin-based chemotherapy, can be achieved since Einhorn and Donohue's landmark 1977 study in TGCT."

This review supports the broad germ-cell tumor platinum sensitivity that underlies ovarian germ-cell tumor treatment.

PMID:37958463 SUPPORT Human Clinical

"The 5-year overall survival (OS) and event-free survival (EFS) rates were 98.3% and 84.9%, respectively."

This ovarian germ cell tumor cohort supports favorable outcomes with bleomycin-containing platinum-based chemotherapy.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

6

Digestive 2

Large Ovarian Mass Abdominal mass (HP:0031500)

Show evidence (1 reference)

PMID:33142349 SUPPORT Human Clinical

"All tumors were unilateral, and the median largest diameter was 129 (range, 38-216) mm."

This imaging cohort supports a large unilateral tumor phenotype for rare ovarian non-dysgerminomatous germ cell tumors.

Abdominal Distention From Tumor Bulk Abdominal distention (HP:0003270)

Show evidence (1 reference)

PMID:33142349 PARTIAL Human Clinical

"Using pattern recognition, the typical ultrasound appearance was a large solid tumor with inhomogeneous echogenicity of the solid tissue and often dispersed cysts which, in most cases, were small and irregular."

This supports large tumor bulk; the abdominal distention phenotype is a clinical mass-effect inference rather than directly measured in the cited abstract.

Metabolism 1

Elevated Alpha-Fetoprotein Elevated circulating alpha-fetoprotein concentration (HP:0006254)

Show evidence (1 reference)

PMID:27401840 SUPPORT Human Clinical

"Data on AFP were available to calculate an early AFP decline in 57 patients."

This supports AFP as a routinely measured and clinically informative serum marker in ovarian yolk sac tumor.

Constitutional 1

Abdominal or Pelvic Pain Abdominal pain (HP:0002027)

Show evidence (1 reference)

PMID:40275685 SUPPORT Human Clinical

"Early diagnosis is common due to the rapid tumor growth and symptoms such as abdominal pain and distension, leading to favorable prognoses when combined with the high chemosensitivity of platinum-based regimens."

This recent review directly supports abdominal pain and distension as presenting symptoms of malignant ovarian germ cell tumors.

Other 2

Elevated Beta-Human Chorionic Gonadotropin

Show evidence (1 reference)

PMID:33142349 SUPPORT Human Clinical

"Beta-human chorionic gonadotropin levels were highest in non-gestational choriocarcinomas and alpha-fetoprotein levels were highest in malignant mixed germ cell tumors."

This supports beta-hCG elevation as a laboratory feature of non-gestational ovarian choriocarcinoma in the non-dysgerminomatous group.

Elevated Lactate Dehydrogenase Increased circulating lactate dehydrogenase concentration (HP:0025435)

Show evidence (1 reference)

PMID:34987988 SUPPORT Human Clinical

"Tumor markers namely AFP, βHCG, and LDH increased in all except the patients with immature teratoma."

This ovarian malignant germ cell tumor case series supports LDH elevation as part of the serum marker pattern outside immature teratoma.

🧬

Genetic Associations

3

Chromosome 12p Gain / Isochromosome 12p (Cytogenetic alteration supporting malignant germ cell tumor biology)

Show evidence (1 reference)

PMID:2302685 SUPPORT Human Clinical

"We have found one or more copies of i(12p) in an ovarian germ cell tumor, histologically a yolk sac tumor."

This cytogenetic report directly supports i(12p) in an ovarian yolk sac tumor, a non-dysgerminomatous malignant ovarian germ cell tumor subtype.

KRAS (Somatic oncogenic alteration in a subset of ovarian yolk sac tumors)

Show evidence (1 reference)

PMID:33435376 SUPPORT Human Clinical

"A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in KRAS, KIT, ARID1A."

This molecular profiling study supports KRAS as a somatic alteration in a subset of ovarian yolk sac tumors; KIT is not included as a curated gene here because it is primarily associated with dysgerminoma rather than the non-dysgerminomatous focus of this page.

PIK3CA (Recurrent alteration reported in persistent and recurrent ovarian yolk sac tumor)

Show evidence (1 reference)

PMID:38733954 SUPPORT Human Clinical

"For the 8 persistent and recurrent OYST: cancer driver genes including ANKRD36, ANKRD62, DNAH8, MUC5B, NUP205, RYR2, STARD9, MUC16, TTN, ARID1A and PIK3CA were frequently mutated; cell cycle, ABC transporters, HR, NHEJ and AMPK signal pathway demonstrated as the most significantly enriched..."

This supports PIK3CA alteration in persistent and recurrent ovarian yolk sac tumor.

💊

Treatments

5

Fertility-Sparing Surgery

Action: surgical procedure MAXO:0000004

Fertility-sparing unilateral salpingo-oophorectomy or oophorectomy with appropriate staging is recommended when oncologically safe because the disease mainly affects adolescents and young adults.

Show evidence (1 reference)

PMID:41001186 SUPPORT Human Clinical

"Fertility-sparing surgery, including unilateral salpingo-oophorectomy with minimal staging, is recommended for adolescent and young adult patients."

This recent management review supports fertility-sparing surgery as a central treatment strategy.

Active Surveillance

Active surveillance with serial tumor markers, imaging, and follow-up is used for selected low-risk or fully resected tumors to avoid unnecessary chemotherapy toxicity, particularly in immature teratoma and trial-defined low-risk germ cell tumor settings.

Show evidence (2 references)

PMID:40275685 SUPPORT Human Clinical

"Fertility-sparing surgery is the cornerstone of treatment for stage I disease, often followed by close surveillance to minimize the long-term toxicities of chemotherapy."

This recent management review supports surveillance after surgery in selected early-stage malignant ovarian germ cell tumors.

clinicaltrials:NCT03067181 SUPPORT Human Clinical

"This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed."

This trial directly models active surveillance for low-risk germ cell tumors and includes ovarian germ cell tumor-relevant populations.

BEP Chemotherapy

Action: chemotherapy MAXO:0000647

Agent: bleomycin ↗ etoposide ↗ cisplatin ↗

Bleomycin, etoposide, and cisplatin chemotherapy is the standard first-line platinum-based regimen for many higher-risk malignant ovarian germ cell tumors.

Mechanism Target:

MODULATES Platinum Sensitivity and Resistance — Cisplatin-based chemotherapy exploits the platinum sensitivity of germ cell tumors while relapse biology and toxicity drive dose optimization.

Show evidence (2 references)

PMID:41001186 SUPPORT Human Clinical

"The bleomycin/etoposide/cisplatin regimen remains the first-line therapy."

This recent management review supports BEP as first-line therapy.

PMID:37958463 SUPPORT Human Clinical

"Among 59 patients who received chemotherapy after initial diagnosis, 57 received BEP (standard dose of bleomycin with 30 units per week, n = 13) or bEP (reduced dose of bleomycin with 15 units/m2 on day 1, n = 44)."

This cohort documents dominant use of BEP or reduced-bleomycin BEP in children, adolescents, and young adults with malignant ovarian germ cell tumors.

Paclitaxel-Carboplatin Chemotherapy

Action: chemotherapy MAXO:0000647

Agent: paclitaxel ↗ carboplatin ↗

Paclitaxel plus carboplatin is under active evaluation and retrospective comparison as a fertility-preserving alternative to BEP in selected patients, but BEP remains the main standard regimen.

Mechanism Target:

MODULATES Platinum Sensitivity and Resistance — Carboplatin-based treatment is being compared against cisplatin-based therapy to reduce toxicity while preserving disease control.

Show evidence (1 reference)

PMID:36890292 PARTIAL Human Clinical

"The PC regimen is as safe as the BEP regimen for MOGCT patients with fertility preservation treatment, and no differences were observed in fertility and clinical prognosis."

This retrospective study supports PC as a potential alternative in fertility-preserving treatment, but prospective confirmation is still needed.

Neoadjuvant Chemotherapy

Action: chemotherapy MAXO:0000647

Neoadjuvant chemotherapy may be considered for selected advanced malignant ovarian germ cell tumors when primary surgery would be excessively morbid, but optimal candidate selection and cycle number remain uncertain.

Show evidence (1 reference)

PMID:37760440 PARTIAL Human Clinical

"In conclusion, NACT may be considered for the management of MOGCT; however, possible candidates for NACT use and an ideal number of NACT cycles remain unknown."

This systematic review supports neoadjuvant chemotherapy as a possible selected strategy while preserving uncertainty.

🔬

Biochemical Markers

4

Alpha-Fetoprotein (Elevated in yolk sac tumor and mixed tumors with yolk sac components)

Show evidence (1 reference)

PMID:27401840 SUPPORT Human Clinical

"The serum AFP decline was calculated with the formula previously developed and validated in male patients with poor prognosis non-seminomatous germ cell tumors."

This supports AFP as a quantitative serum biomarker used for ovarian yolk sac tumor prognosis during chemotherapy.

Beta-Human Chorionic Gonadotropin (Elevated especially in non-gestational ovarian choriocarcinoma)

Show evidence (1 reference)

PMID:33142349 SUPPORT Human Clinical

"Beta-human chorionic gonadotropin levels were highest in non-gestational choriocarcinomas and alpha-fetoprotein levels were highest in malignant mixed germ cell tumors."

This supports beta-hCG as a component-specific biomarker in rare ovarian non-dysgerminomatous germ cell tumors.

Lactate Dehydrogenase (Can be elevated as part of the malignant ovarian germ cell tumor marker panel, especially outside immature teratoma.)

Show evidence (1 reference)

PMID:34987988 SUPPORT Human Clinical

"Tumor markers namely AFP, βHCG, and LDH increased in all except the patients with immature teratoma."

This supports LDH as a serum biomarker measured in ovarian malignant germ cell tumor evaluation.

Circulating miR-371a-3p (Emerging blood-based biomarker for germ cell tumors, including non-teratomatous germ cell tumors; clinical utility in ovarian and pediatric germ cell tumor settings remains under evaluation.)

Show evidence (1 reference)

PMID:38611057 PARTIAL Human Clinical

"Circulating levels of germ cell tumor (GCT)-associated miRNAs, such as miR-371a-3p, can be utilized as efficient and cost-effective alternatives in diagnosing and managing patients presenting with GCTs."

This review supports miR-371a-3p as an emerging GCT-associated circulating biomarker; support is partial because the evidence is germ-cell-tumor broad rather than ovarian non-dysgerminomatous specific.

🔬

Clinical Trials

2

NCT02429687 PHASE_III RECRUITING

Randomized trial comparing paclitaxel/platinum chemotherapy with BEP after surgery in newly diagnosed malignant ovarian germ cell tumor patients.

Show evidence (1 reference)

clinicaltrials:NCT02429687 SUPPORT Human Clinical

"Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery."

This trial directly evaluates a less-toxic platinum/taxane alternative to BEP for malignant ovarian germ cell tumors.

NCT03067181 PHASE_III RECRUITING

Pediatric and adult germ cell tumor trial including active surveillance for low-risk disease and randomized carboplatin- versus cisplatin-based therapy for standard-risk metastatic germ cell tumors.

Show evidence (1 reference)

clinicaltrials:NCT03067181 SUPPORT Human Clinical

"The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors."

This trial is relevant to platinum selection and toxicity reduction across pediatric and adult germ cell tumor treatment, including ovarian germ cell tumors.

{ }

Source YAML

click to show

name: Malignant Non-Dysgerminomatous Germ Cell Tumor Of Ovary
creation_date: "2026-05-07T12:56:22Z"
updated_date: "2026-05-07T13:41:30Z"
synonyms:
- ovarian non-dysgerminomatous germ cell tumor
- non-dysgerminomatous germ cell cancer of ovary
- ovarian nondysgerminomatous germ cell tumor
description: >-
  Malignant non-dysgerminomatous germ cell tumor of ovary is an ovarian malignant
  germ-cell neoplasm category that excludes pure dysgerminoma and includes yolk
  sac tumor, immature teratoma, embryonal carcinoma, non-gestational
  choriocarcinoma, and mixed malignant germ cell tumors. These rare
  non-epithelial ovarian cancers mainly affect adolescents and young adults,
  often present as large unilateral ovarian tumors with germ-cell tumor marker
  abnormalities, and are usually treated with fertility-sparing surgery plus
  platinum-based chemotherapy when risk-adapted surveillance is not sufficient.
categories:
- Gynecologic Cancer
- Germ Cell Neoplasm
- Solid Tumor
parents:
- ovarian malignant germ cell tumor
disease_term:
  preferred_term: malignant non-dysgerminomatous germ cell tumor of ovary
  term:
    id: MONDO:0016096
    label: malignant non-dysgerminomatous germ cell tumor of ovary
definitions:
- name: Non-dysgerminomatous ovarian malignant germ cell tumor definition
  definition_type: CASE_DEFINITION
  description: >-
    Ovarian malignant germ cell tumors arise from ovarian germ cells; the
    non-dysgerminomatous subset excludes pure dysgerminoma and captures malignant
    primitive or teratomatous histologies such as yolk sac tumor, embryonal
    carcinoma, choriocarcinoma, immature teratoma, and mixed malignant germ cell
    tumor.
  scope: Rare gynecologic oncology disease grouping
  evidence:
  - reference: PMID:37372675
    reference_title: "Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Precursory germ cells of the ovary form the basis of GCT. They are
      histologically classified into primitive GCT, teratomas, and monodermal
      and somatic-type tumours associated with dermoid cysts.
    explanation: >-
      This review supports the ovarian germ-cell origin and major histologic
      classification framework used for this non-dysgerminomatous disease entry.
has_subtypes:
- name: Yolk Sac Tumor
  display_name: Ovarian yolk sac tumor
  description: >-
    Endodermal sinus/yolk sac tumor is an aggressive non-dysgerminomatous
    histology that commonly produces alpha-fetoprotein and has clinically
    important marker kinetics during chemotherapy.
  evidence:
  - reference: PMID:27401840
    reference_title: "Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The ovarian yolk sac tumor (OYST) is a very rare malignancy arising in
      young women.
    explanation: This supports ovarian yolk sac tumor as a rare malignant ovarian germ cell tumor subtype.
- name: Immature Teratoma
  display_name: Ovarian immature teratoma
  description: >-
    Malignant teratoma composed of immature tissues; fully resected stage I
    disease is a major management controversy because pediatric and adult
    practices differ on postoperative chemotherapy.
  evidence:
  - reference: PMID:38544795
    reference_title: "Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ovarian immature teratoma (IT) is a rare neoplasm comprising ∼3% of
      ovarian cancers, occurring primarily in young females.
    explanation: This supports immature teratoma as a rare ovarian neoplasm in the target population.
- name: Embryonal Carcinoma
  display_name: Ovarian embryonal carcinoma
  description: >-
    Rare primitive non-dysgerminomatous ovarian germ cell tumor that may occur
    alone or as part of a mixed malignant germ cell tumor.
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To describe the clinical and ultrasound characteristics of three types of
      rare malignant ovarian germ cell tumor: embryonal carcinoma,
      non-gestational choriocarcinoma and malignant mixed germ cell tumor.
    explanation: >-
      This imaging series supports ovarian embryonal carcinoma as one of the rare
      malignant ovarian germ cell tumor types in this non-dysgerminomatous group.
- name: Choriocarcinoma
  display_name: Non-gestational ovarian choriocarcinoma
  description: >-
    Rare trophoblastic non-dysgerminomatous ovarian germ cell tumor that is
    associated with high beta-human chorionic gonadotropin.
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To describe the clinical and ultrasound characteristics of three types of
      rare malignant ovarian germ cell tumor: embryonal carcinoma,
      non-gestational choriocarcinoma and malignant mixed germ cell tumor.
    explanation: >-
      This supports non-gestational ovarian choriocarcinoma as a rare malignant
      ovarian germ cell tumor type.
- name: Mixed Malignant Germ Cell Tumor
  description: >-
    Tumors containing more than one malignant ovarian germ cell component; mixed
    tumors may combine yolk sac tumor, immature teratoma, embryonal carcinoma,
    choriocarcinoma, or dysgerminoma components.
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To describe the clinical and ultrasound characteristics of three types of
      rare malignant ovarian germ cell tumor: embryonal carcinoma,
      non-gestational choriocarcinoma and malignant mixed germ cell tumor.
    explanation: >-
      This supports malignant mixed germ cell tumor as one of the rare malignant
      ovarian germ cell tumor types represented in this entry.
prevalence:
- population: Ovarian cancers
  percentage: 2-5
  notes: Malignant ovarian germ cell tumors are rare relative to epithelial ovarian cancers.
  evidence:
  - reference: PMID:37372675
    reference_title: "Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GCTs represent 2-5% of ovarian cancers, with a yearly incidence of
      4:100,000, and they usually affect young women and adolescents.
    explanation: >-
      This provides the relative frequency of ovarian germ cell tumors among
      ovarian cancers and supports the adolescent/young adult demographic.
progression:
- phase: Adolescent and young adult presentation
  age_range: Adolescence to young adulthood
  notes: Ovarian germ cell tumors are a leading gynecologic cancer in patients younger than 25 years.
  evidence:
  - reference: PMID:37820296
    reference_title: "Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Testicular GCTs (TGCTs) are the most common cancers in 15- to 39-year-old
      men, and ovarian GCTs (OvGCTs) are the leading gynecologic malignancies in
      women younger than 25 years.
    explanation: >-
      This supports adolescent/young adult age enrichment for ovarian germ cell
      tumors.
- phase: Relapse risk and marker normalization
  notes: >-
    Tumor marker normalization after treatment is prognostically important,
    especially for yolk sac tumors and other marker-secreting components.
  evidence:
  - reference: PMID:37958463
    reference_title: "Excellent Outcomes in Children, Adolescents, and Young Adults with Ovarian Germ Cell Tumors Treated by Either Reduced- or Standard-Dose Bleomycin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Normalization of tumor markers within 3 months after surgery was
      significantly associated with better EFS (p < 0.01).
    explanation: >-
      This cohort supports tumor-marker normalization as an outcome-linked
      feature in malignant ovarian germ cell tumor follow-up.
pathophysiology:
- name: Primordial Germ Cell-Derived Malignancy
  description: >-
    The disease arises from ovarian germ-cell lineage cells rather than ovarian
    surface epithelial cells. Malignant transformation creates primitive or
    teratomatous germ-cell histologies that remain biologically distinct from
    common epithelial ovarian carcinomas.
  cell_types:
  - preferred_term: primordial germ cell
    term:
      id: CL:0000670
      label: primordial germ cell
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  biological_processes:
  - preferred_term: germ cell development
    modifier: ABNORMAL
    term:
      id: GO:0007281
      label: germ cell development
  evidence:
  - reference: PMID:33435376
    reference_title: "Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The malignant ovarian GCTs (mOGCTs) are assumed to derive from primordial
      germ cells (PGCs) with inherited or somatically acquired alterations [2].
    explanation: >-
      This source directly supports primordial germ cells as the inferred
      cell-of-origin for malignant ovarian germ cell tumors.
  downstream:
  - target: Non-Dysgerminomatous Differentiation Programs
    description: Transformed germ cells differentiate into embryonic or extraembryonic malignant histologies.
- name: Non-Dysgerminomatous Differentiation Programs
  description: >-
    Non-dysgerminomatous ovarian germ cell tumors show differentiation toward
    embryonic tissues, including embryonal carcinoma and immature teratoma, or
    extraembryonic tissues, including yolk sac tumor and non-gestational
    choriocarcinoma.
  biological_processes:
  - preferred_term: cell differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030154
      label: cell differentiation
  evidence:
  - reference: PMID:33435376
    reference_title: "Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primitive GCTs are subdivided into the ovarian counterpart of the male
      testicular seminoma, dysgerminoma (DG), and non-DGs. The development of
      non-DGs is characterized by differentiation into cell histologies that mimic
      embryonic tissues (embryonal carcinoma (EC), teratoma) and extraembryonic
      tissues (yolk sac tumor (YST) or non-gestational choriocarcinoma (CC))
      (Figure 1) [2].
    explanation: >-
      This supports the specific non-dysgerminomatous differentiation programs
      represented in this entry.
  downstream:
  - target: Large Unilateral Marker-Secreting Ovarian Tumor
    description: Differentiated malignant components form bulky ovarian tumors and secrete component-specific markers.
- name: Yolk Sac Tumor Molecular Alteration
  description: >-
    Ovarian yolk sac tumors have limited molecular data, but profiled tumors can
    harbor clinically relevant alterations in oncogenic signaling and chromatin
    regulatory genes, including KRAS and ARID1A in one series and PIK3CA in
    persistent or recurrent disease.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  - preferred_term: phosphatidylinositol 3-kinase/protein kinase B signal transduction
    modifier: ABNORMAL
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
  genes:
  - preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  - preferred_term: PIK3CA
    term:
      id: hgnc:8975
      label: PIK3CA
  evidence:
  - reference: PMID:33435376
    reference_title: "Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of three patients (33.3% of all patients) harbored targetable
      oncogenic mutations in KRAS, KIT, ARID1A.
    explanation: >-
      This molecular profiling series supports recurrent actionable oncogenic
      alterations in a subset of ovarian yolk sac tumors; KIT is not modeled as
      a gene for this non-dysgerminomatous page because the same paper and the
      wider literature associate KIT most strongly with dysgerminoma biology.
  - reference: PMID:38733954
    reference_title: "Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For the 8 persistent and recurrent OYST: cancer driver genes including
      ANKRD36, ANKRD62, DNAH8, MUC5B, NUP205, RYR2, STARD9, MUC16, TTN, ARID1A
      and PIK3CA were frequently mutated; cell cycle, ABC transporters, HR, NHEJ
      and AMPK signal pathway demonstrated as the most significantly enriched
      pathways; TMB, DNA MMR gene mutation and MSI were significantly higher.
    explanation: >-
      This larger yolk sac tumor series supports molecular alteration of
      persistent or recurrent disease and specifically includes PIK3CA.
  downstream:
  - target: Platinum Sensitivity and Resistance
    description: Molecularly heterogeneous disease remains usually platinum-sensitive, but persistent or recurrent cases need better risk stratification.
- name: Large Unilateral Marker-Secreting Ovarian Tumor
  description: >-
    Non-dysgerminomatous ovarian germ cell tumors often form large unilateral
    ovarian masses. Tumor components can secrete alpha-fetoprotein or
    beta-human chorionic gonadotropin, supporting diagnosis and response
    monitoring.
  locations:
  - preferred_term: ovary
    term:
      id: UBERON:0000992
      label: ovary
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Beta-human chorionic gonadotropin levels were highest in non-gestational
      choriocarcinomas and alpha-fetoprotein levels were highest in malignant
      mixed germ cell tumors.
    explanation: >-
      This supports component-specific tumor marker secretion in rare ovarian
      non-dysgerminomatous germ cell tumor histologies.
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A unilateral, large solid tumor with inhomogeneous echogenicity of the solid
      tissue and with dispersed small cystic areas in a young woman should raise
      the suspicion of a rare malignant germ cell tumor.
    explanation: >-
      This supports the bulky unilateral ovarian mass presentation for the
      non-dysgerminomatous tumor types covered by this imaging series.
  downstream:
  - target: Platinum Sensitivity and Resistance
    description: Diagnosis and monitoring by imaging and serum markers guide surgery, chemotherapy, and follow-up.
- name: Platinum Sensitivity and Resistance
  description: >-
    Most malignant ovarian germ cell tumors are chemosensitive, with
    cisplatin-based regimens producing high survival rates, but relapse,
    persistent disease, and long-term toxicities motivate dose optimization and
    alternatives.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:37820296
    reference_title: "Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Excellent outcomes, even in widely metastatic disease using
      cisplatin-based chemotherapy, can be achieved since Einhorn and Donohue's
      landmark 1977 study in TGCT.
    explanation: >-
      This review supports the broad germ-cell tumor platinum sensitivity that
      underlies ovarian germ-cell tumor treatment.
  - reference: PMID:37958463
    reference_title: "Excellent Outcomes in Children, Adolescents, and Young Adults with Ovarian Germ Cell Tumors Treated by Either Reduced- or Standard-Dose Bleomycin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The 5-year overall survival (OS) and event-free survival (EFS) rates were
      98.3% and 84.9%, respectively.
    explanation: >-
      This ovarian germ cell tumor cohort supports favorable outcomes with
      bleomycin-containing platinum-based chemotherapy.
phenotypes:
- category: Clinical
  name: Large Ovarian Mass
  description: >-
    Patients can present with a large unilateral solid ovarian tumor on imaging;
    clinically this may manifest as an abdominal or pelvic mass.
  phenotype_term:
    preferred_term: abdominal mass
    term:
      id: HP:0031500
      label: Abdominal mass
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All tumors were unilateral, and the median largest diameter was 129 (range,
      38-216) mm.
    explanation: >-
      This imaging cohort supports a large unilateral tumor phenotype for rare
      ovarian non-dysgerminomatous germ cell tumors.
- category: Clinical
  name: Abdominal Distention From Tumor Bulk
  description: Large ovarian tumor size can cause abdominal distention or mass-effect symptoms.
  phenotype_term:
    preferred_term: abdominal distention
    term:
      id: HP:0003270
      label: Abdominal distention
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using pattern recognition, the typical ultrasound appearance was a large
      solid tumor with inhomogeneous echogenicity of the solid tissue and often
      dispersed cysts which, in most cases, were small and irregular.
    explanation: >-
      This supports large tumor bulk; the abdominal distention phenotype is a
      clinical mass-effect inference rather than directly measured in the cited
      abstract.
- category: Clinical
  name: Abdominal or Pelvic Pain
  description: >-
    Rapid growth of malignant ovarian germ cell tumors commonly causes abdominal
    or pelvic pain, sometimes with distension, and can prompt early diagnosis.
  phenotype_term:
    preferred_term: abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early diagnosis is common due to the rapid tumor growth and symptoms such
      as abdominal pain and distension, leading to favorable prognoses when
      combined with the high chemosensitivity of platinum-based regimens.
    explanation: >-
      This recent review directly supports abdominal pain and distension as
      presenting symptoms of malignant ovarian germ cell tumors.
- category: Laboratory
  name: Elevated Alpha-Fetoprotein
  description: >-
    AFP elevation is especially relevant to ovarian yolk sac tumor and mixed
    tumors with yolk sac components, and AFP decline during chemotherapy is
    prognostically informative.
  phenotype_term:
    preferred_term: Elevated circulating alpha-fetoprotein concentration
    term:
      id: HP:0006254
      label: Elevated circulating alpha-fetoprotein concentration
  evidence:
  - reference: PMID:27401840
    reference_title: "Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Data on AFP were available to calculate an early AFP decline in 57
      patients.
    explanation: >-
      This supports AFP as a routinely measured and clinically informative serum
      marker in ovarian yolk sac tumor.
- category: Laboratory
  name: Elevated Beta-Human Chorionic Gonadotropin
  description: >-
    Beta-hCG is particularly associated with non-gestational ovarian
    choriocarcinoma and can help differentiate non-dysgerminomatous components.
  phenotype_term:
    preferred_term: Elevated beta-human chorionic gonadotropin
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Beta-human chorionic gonadotropin levels were highest in non-gestational
      choriocarcinomas and alpha-fetoprotein levels were highest in malignant
      mixed germ cell tumors.
    explanation: >-
      This supports beta-hCG elevation as a laboratory feature of
      non-gestational ovarian choriocarcinoma in the non-dysgerminomatous group.
- category: Laboratory
  name: Elevated Lactate Dehydrogenase
  description: >-
    LDH is part of the standard germ cell tumor marker panel and can be elevated
    in malignant ovarian germ cell tumors, although it is less subtype-specific
    than AFP or beta-hCG.
  phenotype_term:
    preferred_term: Increased circulating lactate dehydrogenase concentration
    term:
      id: HP:0025435
      label: Increased circulating lactate dehydrogenase concentration
  evidence:
  - reference: PMID:34987988
    reference_title: "Unusual Cases of Pure Malignant Germ Cell Tumors of the Ovary: A Case Series on 10 Years Experience at a Tertiary Care Center."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tumor markers namely AFP, βHCG, and LDH increased in all except the
      patients with immature teratoma.
    explanation: >-
      This ovarian malignant germ cell tumor case series supports LDH elevation
      as part of the serum marker pattern outside immature teratoma.
biochemical:
- name: Alpha-Fetoprotein
  biomarker_term:
    preferred_term: Alpha-Fetoprotein
    term:
      id: NCIT:C16278
      label: Alpha-Fetoprotein
  presence: Elevated in yolk sac tumor and mixed tumors with yolk sac components
  evidence:
  - reference: PMID:27401840
    reference_title: "Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The serum AFP decline was calculated with the formula previously developed
      and validated in male patients with poor prognosis non-seminomatous germ
      cell tumors.
    explanation: >-
      This supports AFP as a quantitative serum biomarker used for ovarian yolk
      sac tumor prognosis during chemotherapy.
- name: Beta-Human Chorionic Gonadotropin
  biomarker_term:
    preferred_term: Human Chorionic Gonadotropin
    term:
      id: NCIT:C2275
      label: Human Chorionic Gonadotropin
  presence: Elevated especially in non-gestational ovarian choriocarcinoma
  evidence:
  - reference: PMID:33142349
    reference_title: "Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Beta-human chorionic gonadotropin levels were highest in non-gestational
      choriocarcinomas and alpha-fetoprotein levels were highest in malignant
      mixed germ cell tumors.
    explanation: >-
      This supports beta-hCG as a component-specific biomarker in rare ovarian
      non-dysgerminomatous germ cell tumors.
- name: Lactate Dehydrogenase
  biomarker_term:
    preferred_term: Lactate Dehydrogenase
    term:
      id: NCIT:C25184
      label: Lactate Dehydrogenase
  presence: >-
    Can be elevated as part of the malignant ovarian germ cell tumor marker
    panel, especially outside immature teratoma.
  notes: Less subtype-specific than AFP or beta-hCG.
  evidence:
  - reference: PMID:34987988
    reference_title: "Unusual Cases of Pure Malignant Germ Cell Tumors of the Ovary: A Case Series on 10 Years Experience at a Tertiary Care Center."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tumor markers namely AFP, βHCG, and LDH increased in all except the
      patients with immature teratoma.
    explanation: >-
      This supports LDH as a serum biomarker measured in ovarian malignant germ
      cell tumor evaluation.
- name: Circulating miR-371a-3p
  biomarker_term:
    preferred_term: MicroRNA 371a-3p
    term:
      id: NCIT:C177289
      label: MicroRNA 371a-3p
  presence: >-
    Emerging blood-based biomarker for germ cell tumors, including
    non-teratomatous germ cell tumors; clinical utility in ovarian and pediatric
    germ cell tumor settings remains under evaluation.
  evidence:
  - reference: PMID:38611057
    reference_title: "Advancing GCT Management: A Review of miR-371a-3p and Other miRNAs in Comparison to Traditional Serum Tumor Markers."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Circulating levels of germ cell tumor (GCT)-associated miRNAs, such as
      miR-371a-3p, can be utilized as efficient and cost-effective alternatives
      in diagnosing and managing patients presenting with GCTs.
    explanation: >-
      This review supports miR-371a-3p as an emerging GCT-associated circulating
      biomarker; support is partial because the evidence is germ-cell-tumor
      broad rather than ovarian non-dysgerminomatous specific.
genetic:
- name: Chromosome 12p Gain / Isochromosome 12p
  presence: >-
    Reported in ovarian malignant germ cell tumors, including yolk sac tumor;
    chromosome 12p gain or i(12p) is a characteristic germ cell tumor cytogenetic
    feature but is not expected in many pure immature teratomas.
  association: Cytogenetic alteration supporting malignant germ cell tumor biology
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: PMID:2302685
    reference_title: "i(12p) in a malignant ovarian tumor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have found one or more copies of i(12p) in an ovarian germ cell tumor,
      histologically a yolk sac tumor.
    explanation: >-
      This cytogenetic report directly supports i(12p) in an ovarian yolk sac
      tumor, a non-dysgerminomatous malignant ovarian germ cell tumor subtype.
- name: KRAS
  gene_term:
    preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  association: Somatic oncogenic alteration in a subset of ovarian yolk sac tumors
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: PMID:33435376
    reference_title: "Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A subset of three patients (33.3% of all patients) harbored targetable
      oncogenic mutations in KRAS, KIT, ARID1A.
    explanation: >-
      This molecular profiling study supports KRAS as a somatic alteration in a
      subset of ovarian yolk sac tumors; KIT is not included as a curated gene
      here because it is primarily associated with dysgerminoma rather than the
      non-dysgerminomatous focus of this page.
- name: PIK3CA
  gene_term:
    preferred_term: PIK3CA
    term:
      id: hgnc:8975
      label: PIK3CA
  association: Recurrent alteration reported in persistent and recurrent ovarian yolk sac tumor
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: PMID:38733954
    reference_title: "Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For the 8 persistent and recurrent OYST: cancer driver genes including
      ANKRD36, ANKRD62, DNAH8, MUC5B, NUP205, RYR2, STARD9, MUC16, TTN, ARID1A
      and PIK3CA were frequently mutated; cell cycle, ABC transporters, HR, NHEJ
      and AMPK signal pathway demonstrated as the most significantly enriched
      pathways; TMB, DNA MMR gene mutation and MSI were significantly higher.
    explanation: This supports PIK3CA alteration in persistent and recurrent ovarian yolk sac tumor.
diagnosis:
- name: Imaging and Serum Marker Diagnostic Work-up
  description: >-
    Diagnostic evaluation relies on imaging for ovarian mass detection and
    staging together with serum tumor markers such as AFP, beta-hCG, and LDH.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:36980387
    reference_title: "Therapeutic Management and Prognostic Factors for Ovarian Malignant Tumours in Adolescents: A Comprehensive Review of Current Guidelines."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All guidelines recommend a thorough diagnostic work-up, consisting of both
      imaging tests and serum tumour marker measurement, as well as the use of
      immunohistochemical methods to confirm the diagnosis and complete surgical
      staging prior to constructing the treatment plan.
    explanation: >-
      This guideline review directly supports imaging, serum marker measurement,
      immunohistochemistry, and surgical staging as diagnostic components.
- name: Histopathology and Immunohistochemistry
  description: >-
    Histopathology with immunohistochemical markers differentiates malignant
    ovarian germ cell tumor subtypes, including yolk sac tumor, immature
    teratoma, choriocarcinoma, embryonal carcinoma, mixed tumors, and
    dysgerminoma.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pathology is pivotal for diagnosis, incorporating immunohistochemical
      markers to differentiate malignant ovarian germ cell tumors subtypes,
      including dysgerminomas, yolk sac tumors, and immature teratomas.
    explanation: >-
      This supports histopathology and immunohistochemistry as central
      diagnostic modalities for malignant ovarian germ cell tumor subtyping.
- name: Cytogenetic Testing for Isochromosome 12p
  description: >-
    Molecular or cytogenetic testing for i(12p) can support malignant germ cell
    tumor classification in diagnostically challenging cases.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:2302685
    reference_title: "i(12p) in a malignant ovarian tumor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This chromosome marker is characteristically associated with germ cell
      tumors in males.
    explanation: >-
      Together with the same abstract's ovarian yolk sac tumor finding, this
      supports i(12p) as a germ cell tumor cytogenetic marker relevant to
      ovarian malignant germ cell tumor diagnosis.
treatments:
- name: Fertility-Sparing Surgery
  description: >-
    Fertility-sparing unilateral salpingo-oophorectomy or oophorectomy with
    appropriate staging is recommended when oncologically safe because the disease
    mainly affects adolescents and young adults.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:41001186
    reference_title: "Updates in the Management of Malignant Ovarian Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fertility-sparing surgery, including unilateral salpingo-oophorectomy with
      minimal staging, is recommended for adolescent and young adult patients.
    explanation: >-
      This recent management review supports fertility-sparing surgery as a
      central treatment strategy.
- name: Active Surveillance
  description: >-
    Active surveillance with serial tumor markers, imaging, and follow-up is
    used for selected low-risk or fully resected tumors to avoid unnecessary
    chemotherapy toxicity, particularly in immature teratoma and trial-defined
    low-risk germ cell tumor settings.
  treatment_term:
    preferred_term: active surveillance
  notes: >-
    Preferred-term-only because local MAXO searches for surveillance and
    monitoring did not return a more specific active-surveillance or
    watchful-waiting term.
  evidence:
  - reference: PMID:40275685
    reference_title: "Malignant germ cells tumor of the ovary."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fertility-sparing surgery is the cornerstone of treatment for stage I
      disease, often followed by close surveillance to minimize the long-term
      toxicities of chemotherapy.
    explanation: >-
      This recent management review supports surveillance after surgery in
      selected early-stage malignant ovarian germ cell tumors.
  - reference: clinicaltrials:NCT03067181
    reference_title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This phase III trial studies how well active surveillance help doctors to
      monitor subjects with low risk germ cell tumors for recurrence after their
      tumor is removed.
    explanation: >-
      This trial directly models active surveillance for low-risk germ cell
      tumors and includes ovarian germ cell tumor-relevant populations.
- name: BEP Chemotherapy
  description: >-
    Bleomycin, etoposide, and cisplatin chemotherapy is the standard first-line
    platinum-based regimen for many higher-risk malignant ovarian germ cell tumors.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: bleomycin
      term:
        id: CHEBI:22907
        label: bleomycin
    - preferred_term: etoposide
      term:
        id: CHEBI:4911
        label: etoposide
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
  target_mechanisms:
  - target: Platinum Sensitivity and Resistance
    treatment_effect: MODULATES
    description: >-
      Cisplatin-based chemotherapy exploits the platinum sensitivity of germ cell
      tumors while relapse biology and toxicity drive dose optimization.
  evidence:
  - reference: PMID:41001186
    reference_title: "Updates in the Management of Malignant Ovarian Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The bleomycin/etoposide/cisplatin regimen remains the first-line therapy.
    explanation: This recent management review supports BEP as first-line therapy.
  - reference: PMID:37958463
    reference_title: "Excellent Outcomes in Children, Adolescents, and Young Adults with Ovarian Germ Cell Tumors Treated by Either Reduced- or Standard-Dose Bleomycin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among 59 patients who received chemotherapy after initial diagnosis, 57
      received BEP (standard dose of bleomycin with 30 units per week, n = 13) or
      bEP (reduced dose of bleomycin with 15 units/m2 on day 1, n = 44).
    explanation: >-
      This cohort documents dominant use of BEP or reduced-bleomycin BEP in
      children, adolescents, and young adults with malignant ovarian germ cell tumors.
- name: Paclitaxel-Carboplatin Chemotherapy
  description: >-
    Paclitaxel plus carboplatin is under active evaluation and retrospective
    comparison as a fertility-preserving alternative to BEP in selected patients,
    but BEP remains the main standard regimen.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: paclitaxel
      term:
        id: CHEBI:45863
        label: paclitaxel
    - preferred_term: carboplatin
      term:
        id: CHEBI:31355
        label: carboplatin
  target_mechanisms:
  - target: Platinum Sensitivity and Resistance
    treatment_effect: MODULATES
    description: Carboplatin-based treatment is being compared against cisplatin-based therapy to reduce toxicity while preserving disease control.
  evidence:
  - reference: PMID:36890292
    reference_title: "Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The PC regimen is as safe as the BEP regimen for MOGCT patients with
      fertility preservation treatment, and no differences were observed in
      fertility and clinical prognosis.
    explanation: >-
      This retrospective study supports PC as a potential alternative in
      fertility-preserving treatment, but prospective confirmation is still needed.
- name: Neoadjuvant Chemotherapy
  description: >-
    Neoadjuvant chemotherapy may be considered for selected advanced malignant
    ovarian germ cell tumors when primary surgery would be excessively morbid,
    but optimal candidate selection and cycle number remain uncertain.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
  evidence:
  - reference: PMID:37760440
    reference_title: "Systematic Review of the Survival Outcomes of Neoadjuvant Chemotherapy in Women with Malignant Ovarian Germ Cell Tumors."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In conclusion, NACT may be considered for the management of MOGCT; however,
      possible candidates for NACT use and an ideal number of NACT cycles remain
      unknown.
    explanation: >-
      This systematic review supports neoadjuvant chemotherapy as a possible
      selected strategy while preserving uncertainty.
clinical_trials:
- name: NCT02429687
  phase: PHASE_III
  status: RECRUITING
  description: >-
    Randomized trial comparing paclitaxel/platinum chemotherapy with BEP after
    surgery in newly diagnosed malignant ovarian germ cell tumor patients.
  evidence:
  - reference: clinicaltrials:NCT02429687
    reference_title: "A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Investigators will conduct the trial to determine whether paclitaxel and
      cisplatin (PT) has the same curative effects and less adverse effects than
      bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant
      ovarian germ cell tumor patients after surgery.
    explanation: >-
      This trial directly evaluates a less-toxic platinum/taxane alternative to
      BEP for malignant ovarian germ cell tumors.
- name: NCT03067181
  phase: PHASE_III
  status: RECRUITING
  description: >-
    Pediatric and adult germ cell tumor trial including active surveillance for
    low-risk disease and randomized carboplatin- versus cisplatin-based therapy
    for standard-risk metastatic germ cell tumors.
  evidence:
  - reference: clinicaltrials:NCT03067181
    reference_title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The trial studies whether carboplatin or cisplatin is the preferred
      chemotherapy to use in treating metastatic standard risk germ cell tumors.
    explanation: >-
      This trial is relevant to platinum selection and toxicity reduction across
      pediatric and adult germ cell tumor treatment, including ovarian germ cell tumors.
references:
- reference: DOI:10.3390/diagnostics13061080
  title: "Therapeutic Management and Prognostic Factors for Ovarian Malignant Tumours in Adolescents: A Comprehensive Review of Current Guidelines"
  found_in:
  - Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary-deep-research-falcon.md
  findings:
  - statement: Diagnostic work-up and guideline-based treatment for adolescent ovarian malignant tumors.
    supporting_text: "Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines"
- reference: DOI:10.3390/ijerph20126089
  title: Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours
  found_in:
  - Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary-deep-research-falcon.md
  findings:
  - statement: Epidemiology, classification, diagnosis, molecular biology, and treatment challenges for malignant ovarian germ cell tumors.
    supporting_text: Clinical challenges in the management of malignant ovarian germ cell tumours
- reference: DOI:10.3390/cancers15184470
  title: Systematic Review of the Survival Outcomes of Neoadjuvant Chemotherapy in Women with Malignant Ovarian Germ Cell Tumors
  found_in:
  - Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary-deep-research-falcon.md
  findings:
  - statement: Neoadjuvant chemotherapy outcomes in advanced malignant ovarian germ cell tumors.
    supporting_text: Systematic review of the survival outcomes of neoadjuvant chemotherapy in women with malignant ovarian germ cell tumors
- reference: DOI:10.1200/jco.23.01099
  title: "Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship"
  found_in:
  - Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary-deep-research-falcon.md
  findings:
  - statement: Adolescent and young adult germ cell tumor epidemiology, treatment, genomics, and survivorship context.
    supporting_text: "Adolescent and young adult germ cell tumors: epidemiology, genomics, treatment, and survivorship"
- reference: DOI:10.1016/j.eclinm.2024.102453
  title: "Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective"
  found_in:
  - Malignant_Non_Dysgerminomatous_Germ_Cell_Tumor_Of_Ovary-deep-research-falcon.md
  findings:
  - statement: Pediatric and adult ovarian immature teratoma management consensus and controversy.
    supporting_text: "Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective"
notes: >-
  Curation is intentionally restricted to ovarian non-dysgerminomatous malignant
  germ cell tumors. Mechanisms from epithelial ovarian carcinoma pages should not
  be imported unless evidence specifically supports the germ-cell tumor group.

📚

References & Deep Research

References

5

DOI:10.3390/diagnostics13061080

Therapeutic Management and Prognostic Factors for Ovarian Malignant Tumours in Adolescents: A Comprehensive Review of Current Guidelines

1 finding

Diagnostic work-up and guideline-based treatment for adolescent ovarian malignant tumors.

"Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines"

DOI:10.3390/ijerph20126089

Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours

1 finding

Epidemiology, classification, diagnosis, molecular biology, and treatment challenges for malignant ovarian germ cell tumors.

"Clinical challenges in the management of malignant ovarian germ cell tumours"

DOI:10.3390/cancers15184470

Systematic Review of the Survival Outcomes of Neoadjuvant Chemotherapy in Women with Malignant Ovarian Germ Cell Tumors

1 finding

Neoadjuvant chemotherapy outcomes in advanced malignant ovarian germ cell tumors.

"Systematic review of the survival outcomes of neoadjuvant chemotherapy in women with malignant ovarian germ cell tumors"

DOI:10.1200/jco.23.01099

Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship

1 finding

Adolescent and young adult germ cell tumor epidemiology, treatment, genomics, and survivorship context.

"Adolescent and young adult germ cell tumors: epidemiology, genomics, treatment, and survivorship"

DOI:10.1016/j.eclinm.2024.102453

Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective

1 finding

Pediatric and adult ovarian immature teratoma management consensus and controversy.

"Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective"

Deep Research

1

Falcon ▸

Recent developments (2023–2024 emphasis)

Edison Scientific Literature 33 citations 2026-05-07T09:17:04.335760

1. Disease Information

1.1 What is the disease?

Malignant ovarian germ cell tumors (OvGCTs) arise from primitive germ cells and represent a rare subset of ovarian malignancies. They are often large and rapidly progressive, predominantly affecting adolescents and young adults. (saani2023clinicalchallengesin pages 2-3)

Non‑dysgerminomatous malignant OvGCTs correspond to non‑seminomatous histologies, especially yolk sac tumor, embryonal carcinoma, choriocarcinoma, immature teratoma, and mixed germ cell tumor. (margioulasiarkou2023therapeuticmanagementand pages 1-2, saani2023clinicalchallengesin pages 1-2)

1.2 Key identifiers (ontology/coding)

MONDO: MONDO_0018171 (malignant germ cell tumor of ovary) (OpenTargets Search: ovarian germ cell tumor)
Other identifiers (OMIM/Orphanet/ICD‑10/ICD‑11/MeSH): Not directly retrievable from the currently accessible evidence set and therefore not asserted.

1.3 Synonyms / alternative names

Malignant ovarian germ cell tumor(s) (MOGCTs) (sakaguchimukaida2023systematicreviewof pages 1-2)
Ovarian germ cell tumor (OvGCT) (travis2024adolescentandyoung pages 3-4)
Ovarian non‑seminomatous/non‑dysgerminomatous germ cell tumor (conceptual grouping based on subtype list) (margioulasiarkou2023therapeuticmanagementand pages 1-2, saani2023clinicalchallengesin pages 1-2)

1.4 Evidence type

This report is derived from aggregated disease‑level resources (peer‑reviewed reviews/guideline syntheses and trial registry records), not from individual EHR case series extraction. (margioulasiarkou2023therapeuticmanagementand pages 1-2, saani2023clinicalchallengesin pages 5-6, NCT02429687 chunk 1)

2. Etiology

2.1 Disease causal factors (current understanding)

Developmental origin: OvGCTs are described as largely originating in utero, with incidence peaking in adolescence/young adulthood. (travis2024adolescentandyoung pages 3-4)
Genetic/molecular drivers: OvGCTs show low somatic mutation rates and relatively stable copy number profiles overall, with subtype‑specific alterations (e.g., KRAS in yolk sac tumors) and characteristic chromosomal changes (12p gain in many post‑pubertal GCTs). (travis2024adolescentandyoung pages 3-4)

2.2 Risk factors

Genetic / developmental risk context - Gonadal dysgenesis / disorders of sex development (DSD): Individuals with gonadal dysgenesis have substantially increased risk of OvGCT, with quoted excess risk ranging 0–60% depending on syndrome, and prophylactic gonadectomy is advised for high‑risk syndromes (examples listed: Turner’s and Swyer). (travis2024adolescentandyoung pages 3-4)

Demographic / geographic context - Regional variation in the proportion of ovarian tumors that are OvGCTs is reported (North America ~2%, Europe ~1.3%, Central/South America ~3.9%, Asia ~4.2%). (travis2024adolescentandyoung pages 3-4) - One review notes higher prevalence in women of Asian and African descent and large regional variation in proportion of ovarian tumors classified as GCTs. (saani2023clinicalchallengesin pages 1-2)

Environmental / lifestyle risk factors - No specific, well‑supported environmental or lifestyle risk factors were identified in the retrieved sources.

2.3 Protective factors

No protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No explicit gene–environment interaction evidence was identified in the retrieved evidence.

3. Phenotypes

3.1 Common presenting phenotypes (with suggested HPO terms)

Clinical presentation is commonly dominated by symptoms of a rapidly enlarging pelvic mass. - Abdominal/pelvic pain (HPO: HP:0002027 Abdominal pain) (saani2023clinicalchallengesin pages 2-3) - Palpable abdominal/pelvic mass (HPO: HP:0003270 Abdominal mass; also consider HP:0000023 Abdominal distension) (saani2023clinicalchallengesin pages 2-3)

Age of onset is typically adolescence/young adulthood (HPO context: HP:0003593 Infantile onset not applicable; instead use onset annotations in metadata). OvGCTs are described as leading gynecologic malignancies in women <25 and incidence peaks in adolescence. (travis2024adolescentandyoung pages 3-4)

3.2 Laboratory abnormalities / biomarkers (with suggested HPO terms)

Elevated alpha‑fetoprotein (AFP)—classically with yolk sac tumor; can be elevated in immature teratoma. (HPO: HP:0031963 Increased circulating alpha-fetoprotein) (saani2023clinicalchallengesin pages 2-3, pashankar2024consensusandcontroversy pages 2-3)
Elevated β‑hCG—classically with choriocarcinoma; can be produced by embryonal carcinoma. (HPO: HP:0031936 Elevated human chorionic gonadotropin) (saani2023clinicalchallengesin pages 2-3, saani2023clinicalchallengesin pages 3-5)
Elevated LDH—supportive for dysgerminoma but often included in work‑up panels. (HPO: HP:0031965 Elevated lactate dehydrogenase) (saani2023clinicalchallengesin pages 2-3, margioulasiarkou2023therapeuticmanagementand pages 12-13)

Quantitative data (immature teratoma): In a pediatric trial (INT‑0106) AFP was elevated in 34% of children with pure ovarian immature teratoma (mean 32 ng/mL, range 13–60), versus 83% with Heifetz lesions/microscopic yolk‑sac foci (mean 304 ng/mL, range 80–1045). (pashankar2024consensusandcontroversy pages 2-3)

3.3 Quality of life impact

The disease and its treatment can impact fertility and long‑term health. A 2024 JCO review emphasizes the need to de‑intensify therapy because late effects of cisplatin‑based therapy (e.g., ototoxicity, neurotoxicity, cardiovascular disease) have emerged as important survivorship issues in germ cell tumors. (travis2024adolescentandyoung pages 3-4)

4. Genetic / Molecular Information

4.1 Recurrently implicated genes (somatic; subtype‑dependent)

The retrieved 2023–2024 reviews describe the following patterns: - KRAS recurrent mutations in ovarian yolk sac tumors (travis2024adolescentandyoung pages 3-4) - PIK3CA and AKT1 amplification in ovarian yolk sac tumors (travis2024adolescentandyoung pages 3-4) - KIT mutation/amplification in dysgerminoma (included here for context/contrast) (travis2024adolescentandyoung pages 3-4) - TP53 alterations largely restricted to cisplatin‑resistant GCTs; MDM2 amplification linked to cisplatin resistance (travis2024adolescentandyoung pages 3-4)

Open Targets’ disease‑gene aggregation for “malignant germ cell tumor of ovary” lists evidence linking the disease to KIT, KRAS, TP53, DICER1, CDKN2A, FANCM, among others, with supporting PMIDs surfaced by the platform. (OpenTargets Search: ovarian germ cell tumor)

4.2 Chromosomal abnormalities / structural features

Gain of chromosome 12p / i(12p): described as a near‑universal feature of post‑pubertal GCTs, present in most OvGCTs; pure mature/immature teratomas are notable exceptions. (travis2024adolescentandyoung pages 3-4)
A 2023 review summarizes copy‑number changes and notes 12p gains essentially in all tumors except pure immature teratomas, and reports additional focal deletions in yolk sac tumors. (saani2023clinicalchallengesin pages 9-10)

4.3 Epigenetic information

No disease‑specific epigenetic mechanisms were identified in the retrieved evidence.

4.4 Molecular profiling / emerging biomarkers

Circulating microRNAs: miR‑371~373 and miR‑302 clusters are highlighted as promising serum biomarkers, with the M371 test (miR‑371a‑3p) specifically referenced as a promising circulating biomarker for malignant GCTs (utility in ovarian/pediatric GCTs still being defined). (travis2024adolescentandyoung pages 11-12, saani2023clinicalchallengesin pages 14-16)

5. Environmental Information

No robust environmental toxins, lifestyle exposures, or infectious triggers were identified in the retrieved evidence as causal or modifying factors for malignant ovarian non‑dysgerminomatous GCTs.

6. Mechanism / Pathophysiology

6.1 High‑level causal chain (current model)

1) Developmental mis‑specification or persistence of primordial germ cells (PGCs) (described as in‑utero origin and PGC biology) → 2) acquisition of subtype‑specific genetic/copy‑number changes (e.g., 12p gain in many tumors; KRAS in yolk sac tumors) → 3) emergence of malignant histologies with characteristic differentiation programs (e.g., endodermal differentiation in yolk sac tumors) → 4) clinically rapid growth presenting as pelvic/abdominal mass/pain and secretion of oncofetal markers (AFP, β‑hCG) that enable monitoring. (travis2024adolescentandyoung pages 3-4, saani2023clinicalchallengesin pages 2-3)

6.2 Molecular pathways and cellular processes

PI3K–PTEN–AKT and TSC–mTOR pathways are highlighted in a 2023 review as relevant to follicle/oocyte survival and potentially to tumorigenesis; PTEN loss/hyperactive AKT may promote genomic instability and tumor growth programs. (saani2023clinicalchallengesin pages 9-10)
KIT signaling is discussed as relevant to primordial germ cell biology and is altered in dysgerminoma (context for the broader OvGCT biology). (saani2023clinicalchallengesin pages 8-9, saani2023clinicalchallengesin pages 9-10)

Suggested GO biological process terms (examples): - GO:0008283 cell population proliferation - GO:0006915 apoptotic process - GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway (KIT context) - GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling (PI3K/AKT context)

6.3 Cell types (suggested CL terms)

Primordial germ cell / germ cell (Cell Ontology: e.g., CL:0000670 primordial germ cell; CL:0000016 male germ cell is not appropriate for ovary; use germ‑cell generic terms)
Ovarian somatic support cells are relevant for microenvironment but not directly evidenced in retrieved texts.

7. Anatomical Structures Affected

7.1 Organ/tissue level

Primary organ: ovary (UBERON: UBERON:0000992 ovary)
Tumors are described as usually unilateral in MOGCT systematic review context. (sakaguchimukaida2023systematicreviewof pages 1-2)

7.2 Metastatic/secondary sites (reported patterns)

Recurrences commonly involve the peritoneum and retroperitoneal lymph nodes within the first two years. (saani2023clinicalchallengesin pages 3-5)

Suggested UBERON terms: - UBERON:0002358 peritoneum - UBERON:0002416 retroperitoneum

8. Temporal Development

8.1 Onset

Peak incidence in adolescence/young adulthood; OvGCT incidence in females aged 15–19 is reported as ~1.2 per 100,000, and OvGCTs are the leading gynecologic malignancies in women <25. (travis2024adolescentandyoung pages 3-4)

8.2 Progression/course

Tumors are described as rapidly progressive and large at presentation. (saani2023clinicalchallengesin pages 2-3)
Relapse timing: recurrences commonly within the first two years. (saani2023clinicalchallengesin pages 3-5)

9. Inheritance and Population

9.1 Epidemiology

Fraction of ovarian cancers: ~2–5% (saani2023clinicalchallengesin pages 1-2)
Incidence estimates: ~4 per 100,000/year reported in one review (saani2023clinicalchallengesin pages 1-2); 2.6 per 100,000 girls/year in an adolescent guideline review context (margioulasiarkou2023therapeuticmanagementand pages 1-2); 1.2 per 100,000 in females aged 15–19 (travis2024adolescentandyoung pages 3-4)
Regional proportion among ovarian tumors: North America 2.0%, Europe 1.3%, Central/South America 3.9%, Asia 4.2%. (travis2024adolescentandyoung pages 3-4)

9.2 Inheritance pattern

No Mendelian inheritance pattern is established for malignant ovarian non‑dysgerminomatous GCTs in the retrieved evidence. The 2024 JCO review discusses substantial heritability in testicular GCT and polygenic architecture, suggesting common variant contributions may exist, but this is not a direct inheritance model for ovarian disease. (travis2024adolescentandyoung pages 3-4)

10. Diagnostics

10.1 Clinical tests and biomarkers

Serum markers (core): β‑hCG, AFP, LDH (often CA125 also) are recommended in suspicious ovarian masses, with serial measurement post‑op and before chemo cycles. (margioulasiarkou2023therapeuticmanagementand pages 12-13, saani2023clinicalchallengesin pages 2-3)

Imaging: pelvic ultrasound first; then abdomino‑pelvic CT or MRI and chest imaging (X‑ray or low‑dose CT). PET is reserved for selected cases. (margioulasiarkou2023therapeuticmanagementand pages 12-13, margioulasiarkou2023therapeuticmanagementand pages 4-5)

Pathology/IHC and cytogenetics: immunohistochemistry panels (SALL4, OCT3/4, PLAP, NANOG, AFP, glypican‑3, SOX2/SOX10, etc.) and FISH for isochromosome 12p in difficult cases are recommended. (margioulasiarkou2023therapeuticmanagementand pages 12-13)

10.2 Staging and surgical staging elements

FIGO staging is used; staging surgery for macroscopic stage I includes omentectomy/omental biopsy and peritoneal washings/biopsies, with selective node excision rather than routine lymphadenectomy. (saani2023clinicalchallengesin pages 2-3, margioulasiarkou2023therapeuticmanagementand pages 5-7)

10.3 Differential diagnosis

Not systematically detailed in the retrieved sources; diagnostic IHC/FISH recommendations imply the main differential includes other non‑epithelial ovarian tumors and mixed histologies. (margioulasiarkou2023therapeuticmanagementand pages 12-13)

11. Outcome / Prognosis

11.1 Survival and response

Most patients present with early-stage disease (reported 60–70% early stage). (saani2023clinicalchallengesin pages 5-6)
Stage I outcomes are excellent with ~90% long-term disease-free survival in reported series. (saani2023clinicalchallengesin pages 5-6)
Reported survival with BEP is described as 82–100% for early stage and ~75% for late stage in one review. (saani2023clinicalchallengesin pages 3-5)

11.2 Prognostic factors

Guideline synthesis lists key adverse prognostic factors including stage > I, incomplete resection, and yolk sac histology; premenarche age at diagnosis is also noted as unfavorable. (margioulasiarkou2023therapeuticmanagementand pages 13-14)

12. Treatment

12.1 Standard of care (real-world implementation)

Surgery (fertility-sparing when oncologically safe) - Unilateral salpingo‑oophorectomy/oophorectomy with staging is emphasized; contralateral ovarian biopsy is discouraged when grossly normal. (margioulasiarkou2023therapeuticmanagementand pages 16-17)

Chemotherapy - BEP (bleomycin, etoposide, cisplatin) is the most widely used regimen; typical guidance is 3 cycles after complete resection and 4 cycles if macroscopic residual disease, with bleomycin often omitted after cycle 3 to reduce pulmonary toxicity. (margioulasiarkou2023therapeuticmanagementand pages 16-17)

Surveillance - Active surveillance with serial markers and imaging is recommended for selected early-stage patients with normalizing markers; follow-up can extend up to 10 years in some guidance. (margioulasiarkou2023therapeuticmanagementand pages 16-17)

MAXO suggestions (examples): - MAXO:0000004 surgical procedure (fertility-sparing resection) - MAXO:0000747 chemotherapy (BEP regimen) - MAXO:0000058 active surveillance

12.2 Neoadjuvant chemotherapy (NACT)

A 2023 systematic review/meta-analysis of retrospective series reported that in advanced MOGCT: - NACT was used in ~40% of advanced cases and achieved ~95.8% response rate. - Comparator studies showed broadly similar OS and DFS ranges vs primary debulking surgery (OS 87–100% vs 70–100%; DFS 87–100% vs 70–100%), though evidence quality was limited and bias concerns were noted. (sakaguchimukaida2023systematicreviewof pages 1-2)

12.3 Controversies: immature teratoma adjuvant chemotherapy

A 2024 MaGIC consortium perspective emphasizes that many retrospective/consortium studies show no DFS/OS benefit from adjuvant chemotherapy in fully resected stage I ovarian immature teratoma, and that no randomized trials exist; MaGIC supports surveillance after surgery for pediatric IT regardless of stage/grade and supports surgery alone for adult stage I in the evidence base. (pashankar2024consensusandcontroversy pages 4-6)

A guideline comparison table image illustrates variation by stage/grade among groups (surveillance vs chemotherapy thresholds). (margioulasiarkou2023therapeuticmanagementand media 71d74127)

12.4 Experimental/ongoing trials (ClinicalTrials.gov)

NCT02429687 (MOGCT-01): Randomized Phase 3; post‑surgery stage IIA–IVB MOGCT; paclitaxel+carboplatin vs BEP; primary endpoint PFS (follow-up up to 5 years). URL: https://clinicaltrials.gov/study/NCT02429687 (NCT02429687 chunk 1)
NCT03067181: COG randomized Phase 3 across pediatric/adult GCTs including stage I ovarian immature teratoma and stage I non‑seminomatous malignant ovarian GCTs; includes active surveillance and compares carboplatin‑ vs cisplatin‑based regimens; endpoints include OS/EFS and ototoxicity, plus biomarker correlates (tumor markers and serum miRNA). URL: https://clinicaltrials.gov/study/NCT03067181 (NCT03067181 chunk 1)

13. Prevention

Primary prevention: No specific modifiable environmental risk factors were identified in retrieved evidence.
Secondary prevention: No population screening strategies are established; early diagnosis relies on evaluation of symptoms/mass and tumor markers/imaging. (margioulasiarkou2023therapeuticmanagementand pages 12-13)
Risk‑reduction in high‑risk syndromes: prophylactic gonadectomy is recommended in high‑risk gonadal dysgenesis syndromes. (travis2024adolescentandyoung pages 3-4)

14. Other Species / Natural Disease

No naturally occurring veterinary analogs or cross‑species transmission information were identified in the retrieved evidence.

15. Model Organisms

No specific model organism systems (mouse/zebrafish/cell lines/organoids) were described in the retrieved evidence set.

Recent developments (2023–2024 emphasis)

Consensus/controversy evolution for immature teratoma: 2024 MaGIC perspective advocating surveillance in many settings vs persistent guideline recommendations for adjuvant chemotherapy in adults, highlighting a key practice gap and need for trials. (pashankar2024consensusandcontroversy pages 4-6, pashankar2024consensusandcontroversy pages 6-7)
Treatment optimization / de‑intensification and survivorship: 2024 JCO review emphasizes late effects of cisplatin and the need for innovations and trial designs that span ages/sexes, incorporating molecular risk stratification. (travis2024adolescentandyoung pages 3-4)
NACT evidence consolidation: 2023 systematic review/meta‑analysis provides quantitative synthesis (response ~95.8%, similar survival ranges vs PDS in limited comparative data), motivating prospective evaluation. (sakaguchimukaida2023systematicreviewof pages 1-2)
Biomarker pipeline: circulating miRNAs (miR‑371~373/miR‑302; M371) are highlighted as promising biomarkers, with clinical utility in ovarian/pediatric settings still being defined. (travis2024adolescentandyoung pages 11-12)

Authoritative-source abstract quotations (direct)

Guideline review (adolescents): “All guidelines recommend a thorough diagnostic work-up, consisting of both imaging tests and serum tumour marker measurement, as well as the use of immunohistochemical methods to confirm the diagnosis…” (Diagnostics 2023; URL: https://doi.org/10.3390/diagnostics13061080) (margioulasiarkou2023therapeuticmanagementand pages 1-2)
Clinical challenges review: “GCTs represent 2–5% of ovarian cancers…” (IJERPH 2023; URL: https://doi.org/10.3390/ijerph20126089) (saani2023clinicalchallengesin pages 1-2)
NACT systematic review: “NACT was used in approximately 40% of advanced MOGCT cases, with a response rate of 95.8%.” (Cancers 2023; URL: https://doi.org/10.3390/cancers15184470) (sakaguchimukaida2023systematicreviewof pages 1-2)
AYA GCT review: “OvGCTs … are the leading gynecologic malignancies in women younger than 25 years.” (JCO 2024; URL: https://doi.org/10.1200/jco.23.01099) (travis2024adolescentandyoung pages 3-4)

Notes on evidence gaps

Despite targeted retrieval, the current tool‑accessible corpus did not provide: - ICD‑10/ICD‑11, MeSH, Orphanet, OMIM mappings specific to “malignant non‑dysgerminomatous ovarian germ cell tumor.” - Robust, validated environmental/lifestyle protective factors or gene–environment interaction evidence. - Specific animal models or standardized QoL instrument outcomes for this tumor type.

These items should be filled by direct queries to ontology services (MONDO/MeSH/Orphanet/ICD browsers) and specialized resources (SEER/GBD, GeneReviews/ClinGen/ClinVar, model organism databases) in a follow‑on extraction step.

References

(margioulasiarkou2023therapeuticmanagementand pages 1-2): Chrysoula Margioula-Siarkou, Stamatios Petousis, Georgia Margioula-Siarkou, George Mavromatidis, Fotios Chatzinikolaou, Emmanouel Hatzipantelis, Frédéric Guyon, and Konstantinos Dinas. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics, 13:1080, Mar 2023. URL: https://doi.org/10.3390/diagnostics13061080, doi:10.3390/diagnostics13061080. This article has 20 citations.
(saani2023clinicalchallengesin pages 1-2): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 79 citations.
(OpenTargets Search: ovarian germ cell tumor): Open Targets Query (ovarian germ cell tumor, 26 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(sakaguchimukaida2023systematicreviewof pages 1-2): Hitomi Sakaguchi-Mukaida, Shinya Matsuzaki, Yutaka Ueda, Satoko Matsuzaki, Mamoru Kakuda, Misooja Lee, Satoki Deguchi, Mina Sakata, Michihide Maeda, Reisa Kakubari, Tsuyoshi Hisa, Seiji Mabuchi, and Shoji Kamiura. Systematic review of the survival outcomes of neoadjuvant chemotherapy in women with malignant ovarian germ cell tumors. Cancers, 15:4470, Sep 2023. URL: https://doi.org/10.3390/cancers15184470, doi:10.3390/cancers15184470. This article has 4 citations.
(saani2023clinicalchallengesin pages 2-3): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 79 citations.
(margioulasiarkou2023therapeuticmanagementand pages 12-13): Chrysoula Margioula-Siarkou, Stamatios Petousis, Georgia Margioula-Siarkou, George Mavromatidis, Fotios Chatzinikolaou, Emmanouel Hatzipantelis, Frédéric Guyon, and Konstantinos Dinas. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics, 13:1080, Mar 2023. URL: https://doi.org/10.3390/diagnostics13061080, doi:10.3390/diagnostics13061080. This article has 20 citations.
(saani2023clinicalchallengesin pages 5-6): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 79 citations.
(margioulasiarkou2023therapeuticmanagementand pages 16-17): Chrysoula Margioula-Siarkou, Stamatios Petousis, Georgia Margioula-Siarkou, George Mavromatidis, Fotios Chatzinikolaou, Emmanouel Hatzipantelis, Frédéric Guyon, and Konstantinos Dinas. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics, 13:1080, Mar 2023. URL: https://doi.org/10.3390/diagnostics13061080, doi:10.3390/diagnostics13061080. This article has 20 citations.
(travis2024adolescentandyoung pages 3-4): Lois B. Travis, Darren R. Feldman, Chunkit Fung, Jenny N. Poynter, Michelle Lockley, and A. Lindsay Frazier. Adolescent and young adult germ cell tumors: epidemiology, genomics, treatment, and survivorship. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, pages JCO2301099, Oct 2024. URL: https://doi.org/10.1200/jco.23.01099, doi:10.1200/jco.23.01099. This article has 32 citations.
(pashankar2024consensusandcontroversy pages 2-3): Farzana Pashankar, Matthew J. Murray, Joanna Gell, Nicola MacDonald, Jonathan Shamash, Deborah F. Billmire, Lindsay Klosterkemper, Thomas Olson, Michelle S. Hirsch, Michelle Lockley, Sara Stoneham, and A. Lindsay Frazier. Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the malignant germ cell international consortium perspective. eClinicalMedicine, 69:102453, Mar 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102453, doi:10.1016/j.eclinm.2024.102453. This article has 19 citations and is from a peer-reviewed journal.
(saani2023clinicalchallengesin pages 3-5): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 79 citations.
(margioulasiarkou2023therapeuticmanagementand pages 4-5): Chrysoula Margioula-Siarkou, Stamatios Petousis, Georgia Margioula-Siarkou, George Mavromatidis, Fotios Chatzinikolaou, Emmanouel Hatzipantelis, Frédéric Guyon, and Konstantinos Dinas. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics, 13:1080, Mar 2023. URL: https://doi.org/10.3390/diagnostics13061080, doi:10.3390/diagnostics13061080. This article has 20 citations.
(margioulasiarkou2023therapeuticmanagementand pages 5-7): Chrysoula Margioula-Siarkou, Stamatios Petousis, Georgia Margioula-Siarkou, George Mavromatidis, Fotios Chatzinikolaou, Emmanouel Hatzipantelis, Frédéric Guyon, and Konstantinos Dinas. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics, 13:1080, Mar 2023. URL: https://doi.org/10.3390/diagnostics13061080, doi:10.3390/diagnostics13061080. This article has 20 citations.
(saani2023clinicalchallengesin pages 14-16): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 79 citations.
(saani2023clinicalchallengesin pages 9-10): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 79 citations.
(travis2024adolescentandyoung pages 11-12): Lois B. Travis, Darren R. Feldman, Chunkit Fung, Jenny N. Poynter, Michelle Lockley, and A. Lindsay Frazier. Adolescent and young adult germ cell tumors: epidemiology, genomics, treatment, and survivorship. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, pages JCO2301099, Oct 2024. URL: https://doi.org/10.1200/jco.23.01099, doi:10.1200/jco.23.01099. This article has 32 citations.
(pashankar2024consensusandcontroversy pages 4-6): Farzana Pashankar, Matthew J. Murray, Joanna Gell, Nicola MacDonald, Jonathan Shamash, Deborah F. Billmire, Lindsay Klosterkemper, Thomas Olson, Michelle S. Hirsch, Michelle Lockley, Sara Stoneham, and A. Lindsay Frazier. Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the malignant germ cell international consortium perspective. eClinicalMedicine, 69:102453, Mar 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102453, doi:10.1016/j.eclinm.2024.102453. This article has 19 citations and is from a peer-reviewed journal.
(pashankar2024consensusandcontroversy pages 6-7): Farzana Pashankar, Matthew J. Murray, Joanna Gell, Nicola MacDonald, Jonathan Shamash, Deborah F. Billmire, Lindsay Klosterkemper, Thomas Olson, Michelle S. Hirsch, Michelle Lockley, Sara Stoneham, and A. Lindsay Frazier. Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the malignant germ cell international consortium perspective. eClinicalMedicine, 69:102453, Mar 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102453, doi:10.1016/j.eclinm.2024.102453. This article has 19 citations and is from a peer-reviewed journal.
(pashankar2024consensusandcontroversy pages 7-8): Farzana Pashankar, Matthew J. Murray, Joanna Gell, Nicola MacDonald, Jonathan Shamash, Deborah F. Billmire, Lindsay Klosterkemper, Thomas Olson, Michelle S. Hirsch, Michelle Lockley, Sara Stoneham, and A. Lindsay Frazier. Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the malignant germ cell international consortium perspective. eClinicalMedicine, 69:102453, Mar 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102453, doi:10.1016/j.eclinm.2024.102453. This article has 19 citations and is from a peer-reviewed journal.
(margioulasiarkou2023therapeuticmanagementand pages 7-8): Chrysoula Margioula-Siarkou, Stamatios Petousis, Georgia Margioula-Siarkou, George Mavromatidis, Fotios Chatzinikolaou, Emmanouel Hatzipantelis, Frédéric Guyon, and Konstantinos Dinas. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics, 13:1080, Mar 2023. URL: https://doi.org/10.3390/diagnostics13061080, doi:10.3390/diagnostics13061080. This article has 20 citations.
(saani2023clinicalchallengesin pages 6-8): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 79 citations.
(margioulasiarkou2023therapeuticmanagementand media 71d74127): Chrysoula Margioula-Siarkou, Stamatios Petousis, Georgia Margioula-Siarkou, George Mavromatidis, Fotios Chatzinikolaou, Emmanouel Hatzipantelis, Frédéric Guyon, and Konstantinos Dinas. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics, 13:1080, Mar 2023. URL: https://doi.org/10.3390/diagnostics13061080, doi:10.3390/diagnostics13061080. This article has 20 citations.
(NCT02429687 chunk 1): Beihua Kong. TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors. Beihua Kong. 2015. ClinicalTrials.gov Identifier: NCT02429687
(NCT03067181 chunk 2): Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors. Children's Oncology Group. 2017. ClinicalTrials.gov Identifier: NCT03067181
(NCT03067181 chunk 1): Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors. Children's Oncology Group. 2017. ClinicalTrials.gov Identifier: NCT03067181
(saani2023clinicalchallengesin pages 8-9): Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez, and Stergios Boussios. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health, 20:6089, Jun 2023. URL: https://doi.org/10.3390/ijerph20126089, doi:10.3390/ijerph20126089. This article has 79 citations.
(margioulasiarkou2023therapeuticmanagementand pages 13-14): Chrysoula Margioula-Siarkou, Stamatios Petousis, Georgia Margioula-Siarkou, George Mavromatidis, Fotios Chatzinikolaou, Emmanouel Hatzipantelis, Frédéric Guyon, and Konstantinos Dinas. Therapeutic management and prognostic factors for ovarian malignant tumours in adolescents: a comprehensive review of current guidelines. Diagnostics, 13:1080, Mar 2023. URL: https://doi.org/10.3390/diagnostics13061080, doi:10.3390/diagnostics13061080. This article has 20 citations.

Ask OpenScientist

OpenScientist Report

Definitions

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 What is the disease?

1.2 Key identifiers (ontology/coding)

1.3 Synonyms / alternative names

1.4 Evidence type

2. Etiology

2.1 Disease causal factors (current understanding)

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Common presenting phenotypes (with suggested HPO terms)

3.2 Laboratory abnormalities / biomarkers (with suggested HPO terms)

3.3 Quality of life impact

4. Genetic / Molecular Information

4.1 Recurrently implicated genes (somatic; subtype‑dependent)

4.2 Chromosomal abnormalities / structural features

4.3 Epigenetic information

4.4 Molecular profiling / emerging biomarkers

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 High‑level causal chain (current model)

6.2 Molecular pathways and cellular processes

6.3 Cell types (suggested CL terms)

7. Anatomical Structures Affected

7.1 Organ/tissue level

7.2 Metastatic/secondary sites (reported patterns)

8. Temporal Development

8.1 Onset

8.2 Progression/course

9. Inheritance and Population

9.1 Epidemiology

9.2 Inheritance pattern

10. Diagnostics

10.1 Clinical tests and biomarkers

10.2 Staging and surgical staging elements

10.3 Differential diagnosis

11. Outcome / Prognosis

11.1 Survival and response

11.2 Prognostic factors

12. Treatment

12.1 Standard of care (real-world implementation)

12.2 Neoadjuvant chemotherapy (NACT)

12.3 Controversies: immature teratoma adjuvant chemotherapy

12.4 Experimental/ongoing trials (ClinicalTrials.gov)

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Recent developments (2023–2024 emphasis)

Authoritative-source abstract quotations (direct)

Notes on evidence gaps